Entries by aaron

High resting heart rate may be risk factor for end-stage renal disease

High resting heart rate may independent risk factor for end-stage renal disease suggests a new study published in the Journal of the American Heart Association.  The relationship between resting heart rate (RHR) and the risk of end‐stage renal disease (ESRD) among those without cardiovascular disease remains unclear. We aim to establish temporal consistency and elucidate […]

Elagolix monotherapy Safe Against Heavy Menstrual Bleeding associated with Uterine Leiomyomas

A new phase 4 study published in The Journal of Obstetrics and Gynecology found elagolix 150 mg monotherapy taken once-daily to solve heavy menstrual bleeding associated with uterine leiomyomas were the safe and effective. This offers promise to premenopausal patients aged 18–51 years. This randomized, double-blind, placebo-controlled study assessed  a total of 82 patients, with […]

PFAS exposure tied to reduced bone health in adolescents and young adults

USA: Exposure to per- and polyfluoroalkyl substances (PFAS) is associated with lower bone mineral density (BMD) in adolescence and young adulthood, critical periods for bone development, which may have implications on future bone health and osteoporosis risk in adulthood, a recent study has found.  PFAS manufactured chemicals used in products such as food packaging and […]

Glucocorticoid effective option for preventing delirium after major surgeries

Glucocorticoid effective option for preventing Postoperative delirium among patients undergoing major non-cardiac surgery suggests a new study published in the BMC Anesthesiology. The effects of intravenous glucocorticoids on postoperative delirium (POD) in adult patients undergoing major surgery remain controversial. Therefore, we conducted this meta-analysis to assess whether intravenous glucocorticoids can decrease POD incidence in the […]

Marstacimab Therapy for Hemophilia Shows Long-term Efficacy and Safety

A recent study demonstrated significant efficacy and safety of monoclonal antibody Marstacimab in the long-term management of severe hemophilia A (HA) or hemophilia B (HB) without inhibitors. This outcomes from the pivotal Phase 3 BASIS study could revolutionize the approach to treat bleeding disorders. The findings were published in American Society of Hematology. Marstacimab enhances […]